Stock fact sheet · data as of

Starling Oncology, Inc. (STLN): fair value, margin of safety and Wheel Score

Healthcare · Medical - Care Facilities · United States · Speculative / Distressed

Close6.51
GLS fair value-no model value
Margin of safety-
Wheel Score44Weakout of 100
Health0/9Piotroski F-score
Moat0.0/10GLS 10-year score
Market cap$651M1.3M shares a day
Implied vol.69%near-the-money, 20-60 d
P/E-EPS -0.35
Dividend yieldnone
Beta0.42moves less than the market
Next earnings-no date recorded

Is STLN undervalued?

At 6.51 (close of 16 Oct 2026), STLN has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -0.35, it pays no dividend and its debts exceed what its assets would fetch), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.

The nightly engine files STLN under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for STLN

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-0.6764-110%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target9.00+38%Analysts' average 12-month price target. Not in the average

Quality and financial health

Starling Oncology, Inc. scores only 0 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 0.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC -68.9%, ROE 385.5%, ROA -36.8% - with debt at -6.60 times equity and negative free cash flow.

Starling Oncology, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 5/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score0 / 9ROIC-68.9%
GLS Moat0.0 / 10ROE385.5%
Debt / equity-6.60ROA-36.8%
Free-cash-flow yield-0.5%Payout ratio0%
Institutions5 / 10Insiders · Congress1 · 5 / 10

Wheel Score 44: Weak

With a Wheel Score of 44 Starling Oncology, Inc. sits in the Weak band. The parts - Value 13/25, Health 0/20, Moat 0/15, Premium 18/20, Stability 14/20 - show where: Health (0/20) scores lowest.

Implied volatility is 69% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (18 of 20) because volatility this high usually comes with a reason. The option chain is deep: 64,627 contracts of open interest across all expiries, which means tight fills at most strikes.

Volume runs at 1.3M shares a day on a market cap of $651M, with a beta of 0.42 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 14 of 20.

PartPointsFrom
Value13 / 250% margin of safety
Health0 / 20Piotroski 0/9
Moat0 / 15moat 0.0/10
Premium18 / 20implied volatility 69%
Stability14 / 201.3M shares/day, $651M cap, beta 0.42

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

No upcoming earnings date is recorded for STLN in the nightly calendar.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Care Facilities

The 12 companies below are the closest to Starling Oncology, Inc. by market cap within the Medical - Care Facilities industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
GMRS
GMR Solutions Inc.
10.3926.59+61%38No options$561M
CYH
Community Health Systems, Inc.
2.99154.27+98%45Weak$422M
AUNA
Auna S.A.
5.3029.73+82%39No options$392M
SRTA
Strata Critical Medical, Inc.
4.2811.39+62%45Weak$379M
VMD
Viemed Healthcare, Inc.
9.6914.75+34%77Good$369M
INNV
Innovage Holding Corp.
8.988.21-9%45Weak$1.2B
USPH
U.S. Physical Therapy, Inc.
84.9150.56-68%45Weak$1.3B
AONC
American Oncology Network, Inc.
11.00--29No options$322M
NUTX
Nutex Health, Inc.
200.80732.07+73%39No options$1.4B
PNTG
The Pennant Group, Inc.
40.8226.64-53%51Fair$1.4B
HCSG
Healthcare Services Group, Inc.
21.4345.20+53%82Prime$1.5B
AGL
Agilon Health, Inc.
88.45--37Weak$1.5B

⚖ Compare STLN with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about STLN

Is STLN undervalued right now?

The GLS models could not value STLN (the company lost money over the last twelve months, EPS -0.35, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 6.51 against.

What is the Wheel Score of STLN and what does it mean?

STLN scores 44 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for STLN?

None of the nine GLS models produced a positive value for STLN (the company lost money over the last twelve months, EPS -0.35, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.

When does Starling Oncology, Inc. report earnings next?

No upcoming earnings date is recorded for STLN in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.

Does STLN have listed options, and how liquid are they?

Yes. The nightly snapshot found 74 listed contracts with 64,627 open interest across all expiries and implied volatility of 69% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.